Literature DB >> 8453437

Gastric emptying, body weight and symptoms in primary anorexia nervosa. Long-term effects of cisapride.

G Stacher1, T A Abatzi-Wenzel, S Wiesnagrotzki, H Bergmann, C Schneider, G Gaupmann.   

Abstract

In a double-blind trial, 12 out-patients with primary anorexia nervosa received, for six weeks, either 10 mg cisapride or placebo, three times a day. Cisapride accelerated gastric emptying of a radiolabelled semisolid meal in all six patients; five gained weight and symptoms of gastric retention ameliorated in four. With placebo, three of six had emptying enhanced, four gained weight, and one's symptoms improved. For another six weeks, all patients received cisapride. In five of the patients who had received cisapride, emptying further accelerated or remained stable; in one it slowed. Of the six patients who received placebo, four had emptying accelerated, five gained weight, and symptoms improved in four. Longer administration of cisapride may, by enhancing gastric motor activity, alleviate symptoms of retention and thus help to change eating behaviour.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8453437     DOI: 10.1192/bjp.162.3.398

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  9 in total

1.  Patterns of personality disorders in women with chronic eating disorders.

Authors:  J O Larsson; M Hellzén
Journal:  Eat Weight Disord       Date:  2004-09       Impact factor: 4.652

2.  Anorexia nervosa: Recent research findings and implications for clinical practice.

Authors:  Maria Råstam
Journal:  Eur Child Adolesc Psychiatry       Date:  1994-07       Impact factor: 4.785

Review 3.  Eating disorders in children and adolescents: pharmacological therapies.

Authors:  L A Kotler; B T Walsh
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

4.  Delayed gastric emptying in human immunodeficiency virus infection: correlation with symptoms, autonomic function, and intestinal motility.

Authors:  P J Neild; K S Nijran; E Yazaki; D F Evans; D L Wingate; R Jewkes; B G Gazzard
Journal:  Dig Dis Sci       Date:  2000-08       Impact factor: 3.199

Review 5.  A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders.

Authors:  J Tack; G Coremans; J Janssens
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

6.  Urinary peptide levels in women with eating disorders. A pilot study.

Authors:  M Hellzén; J O Larsson; K L Reichelt; P A Rydelius
Journal:  Eat Weight Disord       Date:  2003-03       Impact factor: 4.652

Review 7.  Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.

Authors:  L R Wiseman; D Faulds
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 8.  Rational therapy of eating disorders.

Authors:  S J Crow; J E Mitchell
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

Review 9.  Gastrointestinal symptoms and disorders in patients with eating disorders.

Authors:  Yasuhiro Sato; Shin Fukudo
Journal:  Clin J Gastroenterol       Date:  2015-10-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.